Rouiller-Fabre, V
An RCT including 85 women with different indications for ICSI who have been supplemented with AOX daily from the cycle preceding ICSI cycle, versus 85 women who were not given any AOX acting as controls, concluded that AOX therapy did not change clinical or laboratory outcomes (225)
Practical Takeaways for Patients If youre considering or already using a GLP-1 agonist and have a history of breast cancer, heres a way to think about it: Current data are reassuring No clear evidence of increased breast cancer risk No obvious signal of worse outcomes or recurrence There may be indirect benefits Better weight control Better diabetes management Both are linked to better breast cancer outcomes There are still unknowns No large, breast-cancer-only randomized trials yet Possible signals for pancreatic and thyroid cancer need more research Your situation is unique Your tumor type, treatments, other conditions (like diabetes or heart disease), and medications all matter This is exactly the kind of decision that should be made with your oncologist and primary care team Final Word Right now, the evidence says: GLP-1 agonists appear safe from a breast cancer perspective, both for risk and for recurrence
10.1016/j.jnutbio.2022.109019 Summary Keywords energy metabolism, gut microbiota, obesity, potential mechanism, strengthening the spleen and dispelling dampness, traditional Chinese medicine Citation Peng H, Jiang J, Tan Z and Jiang P (2026) Gut microbiota and spleen-strengthening and dampness-dispelling therapies in obesity and related metabolic disorders: key mechanisms and therapeutic potential
The first ingredient, dapagliflozin, belongs to a class of drugs called SGLT2 inhibitors
Why choose Well Medical Arts over an online weight loss provider
